The 'top 5 peptides for beginners' TikTok: what's real and what's hype

What did @juanczunigajr actually say?

The creator ran through what he called the five peptides every beginner man should use: Retatrutide (called "Reda") for fat loss, CJC-1295 plus Ipamorelin for growth hormone and muscle, a "Glow Stack" of BPC-157 plus TB-500 plus GHK-Cu for recovery and appearance, NAD+ for energy and mitochondrial function, and Tesamorelin for visceral fat specifically. He framed all five as a clean starting point, low-drama compared to other GLP-1 options, and sufficient to produce "real results."

To his credit, he did not stack all five simultaneously or claim they cure anything outright. He kept the framing general. But several of his specific claims deserve a closer look, and the regulatory status of some of these compounds is more complicated than the video lets on.

Does the science back this up?

Partially, and it varies a lot by peptide. Tesamorelin has the strongest clinical footing of the group. The others range from "promising in early research" to "almost no human data at all."

Tesamorelin is FDA-approved, specifically for HIV-associated lipodystrophy, and the clinical trial data on visceral fat reduction is real. Falutz et al. (2010, New England Journal of Medicine) showed statistically significant reductions in visceral adipose tissue versus placebo. That is not marketing copy. That is a phase 3 RCT.

CJC-1295 and Ipamorelin together do stimulate growth hormone release. A study by Jetté et al. (2005, Journal of Clinical Endocrinology and Metabolism) confirmed CJC-1295 raises GH and IGF-1 in healthy adults, though long-term effects and safety profiles in non-deficient populations are not well characterized.

BPC-157 and TB-500 have generated interest in animal models. Sikiric et al. (2018, Current Pharmaceutical Design) reviewed BPC-157's effects on wound healing and tendon repair in rodents. Human trial data is essentially nonexistent. GHK-Cu has some skin and wound healing data, primarily in vitro. Retatrutide is in phase 2 and 3 trials, not approved, and not legally available through standard channels.

What did they get wrong (or right)?

The creator got the Tesamorelin visceral fat claim largely right. He also correctly noted that BPC-157 and TB-500 are recovery-focused rather than purely cosmetic. Those are fair points. But several things are either wrong or seriously undersold in terms of complexity.

Calling Retatrutide "without all the other issues" compared to other GLP-1s is not supported by current evidence. Retatrutide is a triple agonist (GLP-1, GIP, glucagon) still in clinical trials. Its side effect profile is not fully characterized. The NEJM phase 2 data (Jastreboff et al., 2023) showed significant nausea and GI events. Calling it a clean, low-issue alternative is premature.

NAD+ as a "peptide" is also just incorrect. NAD+ is a coenzyme, not a peptide. Grouping it here muddies what is already a confusing category for beginners. The mitochondrial energy claims for supplemental NAD+ precursors have mixed support. Yoshino et al. (2021, Science) showed metabolic effects of NMN in postmenopausal women, but direct NAD+ supplementation in healthy men is not the same thing.

Calling BPC-157 "BPC 1.7" throughout is a minor error but signals the creator may be working from secondhand information rather than primary sources.

What should you actually know?

Most of these compounds are not FDA-approved for the uses described. That matters for anyone considering them. Tesamorelin is the one exception, though its approval is narrow and specific. BPC-157, TB-500, and GHK-Cu are research chemicals with no approved human indications. Retatrutide is investigational. That does not mean the science is fake, but it does mean access, purity, and dosing are genuinely unresolved questions that no five-minute TikTok can answer.

If you are interested in peptide therapy, the appropriate path is a clinical evaluation with a licensed provider who can assess your actual hormone levels, body composition, and health history. Stacking five compounds without baseline labs is not optimization. It is guesswork. A regulated telehealth platform with licensed clinicians and prescription-only protocols exists precisely because this category requires individualized oversight, not a beginner's checklist from social media.